옵션 체인은 다양한 행사가격과 만기일에 대한 Inovio Pharmaceuticals의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Inovio Pharmaceuticals에 대한 시장 심리를 평가합니다..

Inovio Pharmaceuticals (NASDAQ:INO) 주식, 옵션 체인

Inovio Pharmaceuticals

Inovio Pharmaceuticals Inc is a United States-based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

AVGO

COST

금요일(13일) 아침 미국 주식 선물이 혼조세를 보이는 가운데, 오늘 투자자들의 주목을 받을 수 있는 주식은 다음과 같다. RH, 브로드컴, 51토크 온라인, 이노비오 및 코스트코

금요일 주목해야 할 주식: RH, 브로드컴, 51토크 온라인, 이노비오 및 코스트코

Inovio Pharmaceuticals, Inc. - Common Stock

Inovio Pharmaceuticals Inc

Innodata Inc

IN OVATIONS HOLDINGS INC by In Ovations Holdings, Inc.

In Ovations Holdings Inc

TPT Strategic Inc

Predictiv AI Inc

Innovator ETFs Trust Innovator International Developed Power Buffer ETF November

InfoNow Corp

Biotech

General

INOVIO Announces Phase 1/2 Trial Results Of INO-3107 For Recurrent Respiratory Papillomatosis With 81% Of Patients Requiring Fewer Surgeries; Plans BLA Submission In Mid-2025 For FDA Accelerated Approval, Aiming To Achieve First US DNA Medicine Approval

Inovio Announces That An Abstract Describing The Immunological Activity Of INO-3107 Will Be Presented As A Poster At The American Association For Cancer Research

<a href="https://www.manchestereveningnews.co.uk/news/health/new-case-mpox-detected-uk-30876004">https://www.manchestereveningnews.co.uk/news/health/new-case-mpox-detected-uk-30876004</a>
&nbsp;
A new case of Mpox has been confirmed in the UK, the UK Health Security Agency (UKHSA) has said.
The latest case of Clade Ib Mpox is the seventh confirmed case since October 2024 after a sixth patient <a href="https://www.manchestereveningnews.co.uk/news/uk-news/new-mpox-case-detected-uk-30823540">was admitted to hospital last week</a>.
<a href="https://www.gov.uk/government/news/ukhsa-detects-first-case-of-clade-ib-mpox?utm_medium=email&amp;utm_campaign=govuk-notifications-topic&amp;utm_source=d72f8bd1-0516-4336-9e7d-b4f8a791ba9a&amp;utm_content=immediately">The UKHSA says</a> the infected patient had recently travelled to Uganda and that the risk to the UK population "remains low". The UKHSA and <a href="https://www.manchestereveningnews.co.uk/all-about/nhs">NHS</a> says it will not be disclosing any further details about the infected person.
Professor Susan Hopkins, Chief Medical Adviser at UKHSA, said: "The risk to the UK population remains low. Close contacts have been identified and offered appropriate advice in order to reduce the chance of further spread."
Mpox, previously known as monkeypox, is a rare infection most commonly found in parts of central and east Africa.
There is currently community transmission of the virus in Uganda, which has so far recorded <a href="https://www.afro.who.int/countries/uganda/publication/mpox-outbreak-uganda-situation-update-22-january-2025">2,209 confirmed Mpox cases</a> and 13 deaths since July 2024.
The Clade Ib variant is a new form of the virus, the which the World Health Organisation (WHO) declared as a global health emergency in August.
WHO says common symptoms of Mpox include a skin rash or lesions which can last two to four weeks, as well as a fever, headache, muscle aches, back pain, low energy and swollen lymph nodes.
<a href="https://www.nhs.uk/conditions/mpox/">The NHS says</a> Mpox can be passed on from person to person through:
Close physical contact with Mpox blisters or scabs
Touching clothing, bedding or towels used by someone with Mpox
The coughs or sneezes of a person with Mpox when they're close to you

AEMD

APDN

CMRX

GOVX

MRNA

TNXP

VRAX

"New Case Of Mpox Detected In The UK After 'Concerning' Surge In Cases In Uganda" - Manchester Evening News

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) with a Neutral and lowers the price target from $5 to $3.

Price Target

Analyst Ratings

HC Wainwright & Co. Maintains Neutral on Inovio Pharmaceuticals, Lowers Price Target to $3

JMP Securities analyst Roy Buchanan reiterates Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) with a Market Outperform and maintains $18 price target.

Reiteration

JMP Securities Reiterates Market Outperform on Inovio Pharmaceuticals, Maintains $18 Price Target

Shares of Inovio Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) pulled back by 5.3% to $2.16 during Wednesday's session, following a <a href="https://www.benzinga.com/news/25/01/42857690/why-inovio-pharmaceuticals-ino-stock-is-skyrocketing">strong rally</a> Tuesday.
The decline may be attributed to profit-taking, as investors assess renewed focus on respiratory illnesses, with increased cases of influenza, COVID-19 and RSV <a href="https://www.benzinga.com/general/biotech/25/01/42854890/us-records-first-human-bird-flu-death-high-levels-of-respiratory-illnesses-vaccine-stocks-rally">driving interest</a> in vaccine developers.
What Else: Inovio's lead candidate, INO-4800, a DNA-based COVID-19 vaccine, remains a key focus among vaccine-makers, particularly as alternative vaccine technologies gain traction. The company is also advancing its broader pipeline, which includes vaccines for RSV, MERS and other pathogens.
While Wednesday's profit-taking reflects typical market volatility following a sharp rise, Inovio's long-term prospects remain tied to its ability to advance its portfolio and demonstrate the effectiveness of its DNA-based vaccine platform in addressing global health challenges.
Read Also: <a href="https://www.benzinga.com/25/01/42878295/quantum-stocks-tumble-why-rigetti-ionq-and-d-wave-are-falling">Quantum Stocks Tumble: Why Rigetti, IonQ and D-Wave Are Falling</a>
<h2 class="wp-block-heading">How To Buy INO Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Inovio Pharmaceuticals&#8217; case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, INO has a 52-week high of $14.75 and a 52-week low of $1.74.

What's Going On With Inovio Pharmaceuticals (INO) Stock?

Inovio Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) shares are trading higher by 17.9% to $2.27 Tuesday afternoon amid growing concerns about <a href="https://www.cdc.gov/respiratory-viruses/data/index.html#cdc_data_surveillance_section_2-weekly-national-summary">respiratory illnesses</a>, including seasonal influenza, COVID-19 and RSV. Increased attention to vaccine and therapeutic solutions this week has increased interest in biotechnology stocks focused on infectious diseases.
The Louisiana Department of Health also <a href="https://www.ldh.la.gov/news/H5N1-death">reported</a> the first U.S. H5N1 death, a patient over 65 with underlying conditions who contracted the virus from birds, with no further cases or person-to-person spread. This may increase demand for avian flu vaccines and research.
Read Also: <a href="https://www.benzinga.com/general/biotech/25/01/42854890/us-records-first-human-bird-flu-death-high-levels-of-respiratory-illnesses-vaccine-stocks-rally">US Records First Human Bird Flu Death, High Levels Of Respiratory Illnesses: Vaccine Stocks Rally</a>
What Else: Inovio is known for its DNA-based vaccine technology platform. The company's lead product candidate, INO-4800, a DNA-based COVID-19 vaccine, remains a focal point of its pipeline, particularly for markets seeking alternatives to traditional mRNA vaccines.
Inovio's portfolio extends beyond COVID-19. The company is advancing research on vaccines targeting a variety of infectious diseases and cancers, with recent progress in its RSV and MERS vaccine programs. 
Additionally, its SynCon platform, which underpins its DNA medicines, enables the design and production of new vaccine candidates, potentially positioning Inovio as a player in responding to emerging global health threats.
Read Also: <a href="https://www.benzinga.com/news/25/01/42851023/why-novavax-nvax-stock-is-rising">Why Novavax Stock Is Rising</a>
<h2 class="wp-block-heading">How To Buy INO Stock</h2>
By now you're likely curious about how to participate in the market for Inovio Pharmaceuticals &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.
In the case of Inovio Pharmaceuticals, which is trading at $2.33 as of publishing time, $100 would buy you 42.92 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.

Why Inovio Pharmaceuticals (INO) Stock Is Skyrocketing

WIIM

BNTX

CVAC

NVAX

Shares of vaccine makers are trading higher after the first bird flu death was reporting in the US. Additionally, a recent CDC report noted an increase in acute respiratory illness activity.

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Rocket Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKT#NASDAQ">RCKT</a>)</h3>
<ul>
<li>On Dec. 11, Rocket Pharmaceuticals announced a $165 million upsized public offering of 13.2 million shares at $12.50 per share. The company's stock fell around 10% over the past month and has a <a href="https://www.benzinga.com/quote/RCKT">52-week low of $11.15</a>.</li>
<li>RSI Value: 26.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>RCKT Price Action: Shares of Rocket Pharmaceuticals fell 1.3% to close at $12.56 on Friday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010625&amp;t=be2bearmibe3na1">latest RCKT news</a>.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010625&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="893" height="843" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/06071723/image-18.png" alt="" class="wp-image-719464" style="width:556px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/06071723/image-18.png 893w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/06071723/image-18-300x283.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/06071723/image-18-768x725.png 768w" sizes="(max-width: 893px) 100vw, 893px" /></a></figure>
<h3 class="wp-block-heading">Inovio Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On Dec. 13, Inovio Pharmaceuticals announced a public offering of 10 million shares for gross proceeds of $30 million.. The company's stock fell around 53% over the past month and <a href="https://www.benzinga.com/quote/INO">has a 52-week low</a> of $1.74.</li>
<li>RSI Value: 18.5</li>
<li>INO Price Action: Shares of Inovio Pharmaceuticals gained 7.7% to close at $1.96 on Friday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010625&amp;t=be2bearmibe3na1">trend in INO stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010625&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="923" height="848" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/06071810/image-19.png" alt="" class="wp-image-719466" style="width:677px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/06071810/image-19.png 923w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/06071810/image-19-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/06071810/image-19-768x706.png 768w" sizes="(max-width: 923px) 100vw, 923px" /></a></figure>
<h3 class="wp-block-heading">Outlook Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTLK#NASDAQ">OTLK</a>)</h3>
<ul>
<li>On Dec. 27, Outlook Therapeutics announced a year-over-year increase in FY24 EPS results. &#8220;Over the course of the past year, our team has continued to execute and progress the development of ONS-5010/LYTENAVA&#x2122; in Europe and the United States. Following the receipt of our first positive reimbursement decision worldwide for LYTENAVA&#x2122; from NICE in the United Kingdom, our team continues to make preparations for commercial launch in the UK and Germany, which is expected in the first half of calendar 2025,&#8221; commented Lawrence Kenyon, Chief Financial Officer and Interim Chief Executive Officer of Outlook Therapeutics. The company's stock fell around 72% over the past six months and has a 52-week <a href="https://www.benzinga.com/quote/OTLK">low of $0.87</a>.</li>
<li>RSI Value: 26.9</li>
<li>OTLK Price Action: Shares of Outlook Therapeutics gained 8.8% to close at $2.24 on Friday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010625&amp;t=be2bearmibe3na1">breakout in OTLK shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010625&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="917" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/06071849/image-20.png" alt="" class="wp-image-719469" style="width:612px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/06071849/image-20.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/06071849/image-20-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/06071849/image-20-768x701.png 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/01/42791037/delta-air-lines-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">Delta Air Lines Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a></li>
</ul>

Long Ideas

OTLK

RCKT

Top 3 Health Care Stocks That Could Blast Off This Month

<h3>Gainers</h3>
<ul>
<li>Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) stock moved upwards by 18.7% to $4.31 during Friday's pre-market session. The market value of their outstanding shares is at $46.4 million. </li>
<li>Senseonics Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SENS#AMEX">SENS</a>) shares rose 16.0% to $0.5. The market value of their outstanding shares is at $297.7 million. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock rose 15.81% to $2.49. The market value of their outstanding shares is at $28.6 million. </li>
<li>Cadrenal Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVKD#NASDAQ">CVKD</a>) stock rose 13.62% to $13.18. The company's market cap stands at $21.8 million. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) shares rose 13.33% to $3.91. The company's market cap stands at $3.7 million. </li>
<li>Barinthus Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRNS#NASDAQ">BRNS</a>) stock moved upwards by 12.82% to $0.93. The market value of their outstanding shares is at $36.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Repare Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>) stock decreased by 41.0% to $2.34 during Friday's pre-market session. The market value of their outstanding shares is at $99.5 million. </li>
<li>Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) shares declined by 32.48% to $2.54. The company's market cap stands at $66.2 million. </li>
<li>Candel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) stock fell 30.62% to $6.8. The market value of their outstanding shares is at $220.8 million. </li>
<li>Know Labs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KNW#AMEX">KNW</a>) shares fell 20.84% to $0.19. The company's market cap stands at $20.5 million. </li>
<li>Bicycle Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCYC#NASDAQ">BCYC</a>) stock declined by 15.77% to $16.94. The company's market cap stands at $1.1 billion. </li>
<li>Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) shares decreased by 14.15% to $2.19. The market value of their outstanding shares is at $431.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BCYC

BRNS

CADL

CVKD

ESPR

ISPC

LTRN

RPTX

SENS

12 Health Care Stocks Moving In Friday's Pre-Market Session

U.S. stocks traded mixed toward the end of trading, with the S&amp;P 500 edging lower on Friday.
The Dow traded down 0.14% to 43,851.19 while the NASDAQ rose 0.04% to 19,911.75. The S&amp;P 500 also fell, dropping, 0.04% to 6,048.90.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42460676/jim-cramer-amd-ceo-lisa-su-built-an-amazing-company">Jim Cramer Says This CEO &#8216;Built An Amazing Company,&#8217; Recommends Buying Netflix</a>
Leading and Lagging Sectors Information technology shares jumped by 0.3% on Friday.
In trading on Friday, materials shares fell by 1.1%.
Top Headline
U.S. import prices increased by 0.1% from the previous month in November. Export prices came in unchanged for November compared to a 1% gain in the previous month.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>WISeKey International Holding AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKEY#NASDAQ">WKEY</a>) shares shot up 86% to $6.09 following the company's confirmation of its subsidiary WISeSat.Space's satellite launch with SpaceX. The goal of the launch is to deploy post-quantum-ready next-generation WISeSat satellites. This will showcase the combination of WISeKey's Root of Trust and SEALSQ's Post-Quantum Chips, providing security against emerging quantum threats.</li>
<li>Shares of Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) got a boost, surging 22% to $220.24 after the company posted better-than-expected earnings for its fourth quarter.</li>
<li>RH &nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) shares were also up, gaining 13% to $430.78 after the company raised its guidance. Also, Baird maintained a Neutral rating on the stock and raised its price target from $300 to $400.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Repare Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>) shares dropped 57% to $1.6895 after the company reported results of Lunresertib and Camonsertib combination from MYTHIC Phase 1 gynecologic expansion clinical trial.</li>
<li>Shares of 22nd Century Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) were down 35% to $0.0480 after the company announced a 1-for-135 reverse stock split.</li>
<li>Inovio Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) was down, falling 38% to $2.34 after the company announced a public offering of 10 million shares for gross proceeds of $30 million.</li>
</ul>
Commodities In commodity news, oil traded up 1.8% to $71.25 while gold traded down 1.3% at $2,675.00.
Silver traded down 1.8% to $31.050 on Friday, while copper fell 1.1% to $4.1985.
Euro zone
European shares closed lower today. The eurozone's STOXX 600 fell 0.53%, Germany's DAX fell 0.10% and France's CAC 40 fell 0.15%. Spain's IBEX 35 Index slipped 0.11%, while London's FTSE 100 fell 0.14%.
Asia Pacific Markets
Asian markets closed mostly lower on Friday, with Japan's Nikkei 225 falling 0.95%, Hong Kong's Hang Seng Index dipping 2.09%, China's Shanghai Composite Index tumbling 2.01% and India's BSE Sensex gaining 1.04%.
Economics
<ul>
<li>U.S. import prices increased by 0.1% from the previous month in November.</li>
<li>U.S. export prices came in unchanged for November compared to a 1% gain in the previous month.</li>
<li>The total number of active U.S. oil rigs came in unchanged at 482 rigs this week, Baker Hughes Inc reported.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42483544/how-to-earn-500-a-month-from-meta-stock">How To Earn $500 A Month From Meta Stock</a></li>
</ul>

Equities

Eurozone

Commodities

Intraday Update

WKEY

XXII

Gold Down Over 1%; Inovio Pharmaceuticals Shares Plummet

U.S. stocks traded lower midway through trading, with the Nasdaq Composite down around 0.2% on Friday.
The Dow traded down 0.20% to 43,824.10 while the NASDAQ fell 0.17% to 19,869.43. The S&amp;P 500 also fell, dropping, 0.14% to 6,042.84.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42460676/jim-cramer-amd-ceo-lisa-su-built-an-amazing-company">Jim Cramer Says This CEO &#8216;Built An Amazing Company,&#8217; Recommends Buying Netflix</a>
Leading and Lagging Sectors Utilities shares jumped by 0.3% on Friday.
In trading on Friday, communication services shares fell by 0.8%.
Top Headline
Shares of RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) rose around 15% on Friday after the company released quarterly results.
RH posted downbeat earnings and sales results for its third quarter. However, the company raised revenue guidance across the board based on current trends. The company expects fourth-quarter demand growth of 20% to 22%, and fourth-quarter revenue growth of 18% to 20%, according to data from Benzinga Pro.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>WISeKey International Holding AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKEY#NASDAQ">WKEY</a>) shares shot up 97% to $6.46. WISeKey announced WISeSat satellite launch with SpaceX on Jan. 14, 2025.</li>
<li>Shares of Loop Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOOP#NASDAQ">LOOP</a>) got a boost, surging 38% to $1.7020. Loop Industries completed convertible preferred financing with Reed Societe Generale Group.</li>
<li>SoundHound AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) shares were also up, gaining 20% to $16.38.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Repare Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>) shares dropped 50% to $1.9987 after the company reported results of Lunresertib and Camonsertib combination from MYTHIC Phase 1 gynecologic expansion clinical trial.</li>
<li>Shares of 22nd Century Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) were down 37% to $0.0461 after the company announced a 1-for-135 reverse stock split.</li>
<li>Inovio Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) was down, falling 41% to $2.2350 after the company announced a public offering of 10 million shares for gross proceeds of $30 million.</li>
</ul>
Commodities In commodity news, oil traded up 1.4% to $70.97 while gold traded down 1% at $2,682.30.
Silver traded down 2% to $30.985 on Friday, while copper fell 1.2% to $4.1940.
Euro zone
European shares closed lower today. The eurozone's STOXX 600 fell 0.53%, Germany's DAX fell 0.10% and France's CAC 40 fell 0.15%. Spain's IBEX 35 Index slipped 0.11%, while London's FTSE 100 fell 0.14%.
Asia Pacific Markets
Asian markets closed mostly lower on Friday, with Japan's Nikkei 225 falling 0.95%, Hong Kong's Hang Seng Index dipping 2.09%, China's Shanghai Composite Index tumbling 2.01% and India's BSE Sensex gaining 1.04%.
Economics
<ul>
<li>U.S. import prices increased by 0.1% from the previous month in November.</li>
<li>U.S. export prices came in unchanged for November compared to a 1% gain in the previous month.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42483544/how-to-earn-500-a-month-from-meta-stock">How To Earn $500 A Month From Meta Stock</a></li>
</ul>

LOOP

SOUN

Crude Oil Gains Over 1%; RH Shares Jump On Strong Forecast

U.S. stocks traded mixed this morning, with the Dow Jones index down around 0.1% on Friday.
Following the market opening Friday, the Dow traded down 0.09% to 43,874.75 while the NASDAQ rose 0.42% to 19,987.05. The S&amp;P 500 also rose, gaining, 0.14% to 6,059.64.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42460676/jim-cramer-amd-ceo-lisa-su-built-an-amazing-company">Jim Cramer Says This CEO &#8216;Built An Amazing Company,&#8217; Recommends Buying Netflix</a>
Leading and Lagging Sectors Information technology shares jumped by 1% on Friday.
In trading on Friday, materials shares fell by 1.1%.
Top Headline
Shares of Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) jumped around 22% on Friday after the company posted better-than-expected earnings for its fourth quarter.
The company said it sees first-quarter revenue of approximately $14.6 billion, versus the $14.612 billion estimate. The company also issued adjusted EBITDA guidance of approximately 66 percent of projected revenue for the first quarter.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>WISeKey International Holding AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKEY#NASDAQ">WKEY</a>) shares shot up 75% to $5.74. WISeKey announced WISeSat satellite launch with SpaceX on Jan. 14, 2025.</li>
<li>Shares of Loop Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOOP#NASDAQ">LOOP</a>) got a boost, surging 35% to $1.6693. Loop Industries completed convertible preferred financing with Reed Societe Generale Group.</li>
<li>TruGolf Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUG#NASDAQ">TRUG</a>) shares were also up, gaining 35% to $0.7034 after jumping around 18% on Thursday.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Repare Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>) shares dropped 48% to $2.08 after the company reported results of Lunresertib and Camonsertib combination from MYTHIC Phase 1 gynecologic expansion clinical trial.</li>
<li>Shares of 22nd Century Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) were down 42% to $0.0425 after the company announced a 1-for-135 reverse stock split.</li>
<li>Inovio Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) was down, falling 40% to $2.2701 after the company announced a public offering of 10 million shares for gross proceeds of $30 million.</li>
</ul>
Commodities In commodity news, oil traded up 0.9% to $70.65 while gold traded down 1.2% at $2,676.40.
Silver traded down 2.5% to $30.830 on Friday, while copper fell 1.2% to $4.1950.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.55%, Germany's DAX fell 0.15% and France's CAC 40 fell 0.18%. Spain's IBEX 35 Index slipped 0.14%, while London's FTSE 100 fell 0.33%.
Asia Pacific Markets
Asian markets closed mostly lower on Friday, with Japan's Nikkei 225 falling 0.95%, Hong Kong's Hang Seng Index dipping 2.09%, China's Shanghai Composite Index tumbling 2.01% and India's BSE Sensex gaining 1.04%.
Economics
<ul>
<li>U.S. import prices increased by 0.1% from the previous month in November.</li>
<li>U.S. export prices came in unchanged for November compared to a 1% gain in the previous month.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42483544/how-to-earn-500-a-month-from-meta-stock">How To Earn $500 A Month From Meta Stock</a></li>
</ul>

TRUG

US Stocks Mixed; Broadcom Shares Surge On Upbeat Earnings

Inovio Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) shares are trading lower by 40% to $2.23 during Friday&#8217;s session after the company <a href="https://www.benzinga.com/pressreleases/24/12/n42481116/inovio-announces-pricing-of-30-million-public-offering">priced a public offering</a> of 10 million shares of common stock and accompanying warrants.
The shares are priced at $3.00 each, with warrants exercisable at $3.76 per share, potentially raising $30 million in gross proceeds before expenses and commissions.
The offering, managed by Oppenheimer &amp; Co., Citizens JMP and Stephens Inc., is set to close on December 16, pending customary conditions.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42483141/hershey-merger-talks-fail">Hershey Merger Talks Melt: Did High Cocoa Prices, Mondelez Buyback Program Hurt Deal?</a>
<h2 class="wp-block-heading">Should I Sell My INO Stock?</h2>
When deciding to hold on to or sell a stock, investors should consider their time horizon, unrealized gains and total return.
Shares of Inovio Pharmaceuticals have decreased by 51.14% in the past year. An investor who bought shares of Inovio Pharmaceuticals at the beginning of the year would take a loss of $4.49 per share if they sold it today. The stock has fallen 52.2% over the past month, meaning an investor who bought shares on Nov. 1 would see a capital loss of $3.24.
For access to advanced charting and analysis tools and stock data, check out <a href="https://pro.benzinga.com/">Benzinga PRO. Try it for free.</a> 
INO has a 52-week high of $14.75 and a 52-week low of $2.20.

Why Inovio Pharmaceuticals (INO) Stock Is Down 40%

Inovio Pharmaceuticals shares are trading lower after the company announced a public offering of 10 million shares for gross proceeds of $30 million.

Health Care

Financing

Offerings

Inovio Pharmaceuticals Priced An Underwritten Public Offering Of 10M Shares And Accompanying Warrants To Purchase 10M Shares At An Exercise Price Of $3.76/Share, At A Combined Public Offering Price Of $3/Share And Accompanying Warrant, With Gross Proceeds Of $30M

U.S. stock futures advanced on Friday in premarket hours after declining in trade on Thursday. The futures of all four major indices were trading higher.
The 10-year and two-year Treasury notes yielded 4.33% and 4.19%, respectively. Traders await the import price index data, which will be released later today.
Wall Street is waiting for the Federal Reserve&#8217;s policy meeting next week. Federal Reserve officials are currently in a quiet period ahead of their December meeting.
November inflation data was in line with analyst expectations, shooting up the probability of a further 25 basis point rate cut in December rose to 96.7% versus 86% probability a week ago, according <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">to</a> CME Group&#8217;s FedWatch tool.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.65%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.33%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.23%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.29%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Friday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was up 0.41% to $606.79&nbsp;and the Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) jumped 0.76% to $530.49, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Cues From The Last Session
<a href="https://www.benzinga.com/news/earnings/24/12/42478606/dow-dips-more-than-200-points-following-inflation-data-nvidia-and-amd-decline-fear-greed-index-remains-in-neutral-zone">U.S. stocks closed lower</a> on Thursday, with the Dow Jones shedding over 200 points. The market reacted to fresh inflation data and weaker-than-expected guidance from tech giants.
Technology stocks were among the day&#8217;s biggest losers. Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares dipped over 1%, while Adobe Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) plummeted more than 13% after issuing a disappointing 2025 outlook.
On the economic front, initial jobless claims rose to 242,000, higher than the estimated 220,000. Core producer prices increased by 0.2% month-over-month, aligning with market expectations.
Most S&amp;P 500 sectors ended the day in the red, with healthcare, consumer discretionary, and communication services bearing the brunt of the decline.
However, consumer staples bucked the trend and closed higher.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-0.66%</td>
<td>19.902.84</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.54%</td>
<td>6,051.25</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.53%</td>
<td>43,914.12</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-1.38%</td>
<td>2,361.08</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts
Picking up from Thursday&#8217;s session, Jason Goepfert, the founder of SentimenTrader, said, &#8220;This will be the S&amp;P 500&#8217;s 9th consecutive session with negative breadth. That&#8217;s happened fewer than 20 times in ~70 years. On average, the S&amp;P has been -12% from its high during these streaks.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">This will be the S&amp;P 500&#39;s 9th consecutive session with negative breadth. That&#39;s happened fewer than 20 times in ~70 years. On average, the S&amp;P has been -12% from its high during these streaks. Today marks the closest the S&amp;P has been to its high. The 2 most similar were Dec… <a href="https://t.co/rxHkoG1AzD">pic.twitter.com/rxHkoG1AzD</a>
&mdash; Jason Goepfert (@jasongoepfert) <a href="https://twitter.com/jasongoepfert/status/1867309528573956329?ref_src=twsrc%5Etfw">December 12, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Talking about the future of AI, BlackRock in their 2025 outlook said, &#8220;We think the AI mega force will benefit U.S. stocks more and that's why we stay overweight, particularly relative to international peers such as European stocks.&#8221;
The note added that the &#8220;key signposts&#8221; for them to change their views will include any &#8220;surge in long-term bond yields or an escalation in trade protectionism.&#8221;
The note also added that BlackRock has conviction in U.S. equities outperforming their international peers. &#8220;We recognize valuations are rich in U.S. equities but don't see them as a near-term market driver,&#8221; it added.
According to Charles Schwab&#8217;s 2025 outlook, the volatility backdrop is likely to be different from what investors got used to in 2024. &#8220;The likelihood of a similar dynamic in 2025 is low, in our opinion,&#8221; the note said.
&#8220;Starting with where we are now, though, the market is in a relatively healthy position. As shown in the chart below, the S&amp;P 500 is comfortably above its 50 and 200-day moving averages; and when its 50 DMA was above its 200 DMA historically, the average annualized gain for the index (going back to the late 1920s) was 9.2%. There is strong momentum heading into the new year.&#8221;
However, &#8220;If inflation volatility picks back up, which will become clearer after tariff and labor policy implementations, there could be more risks to stocks via bonds,&#8221; Schwab note adds.
See Also:&nbsp;<a href="https://www.benzinga.com/money/how-to-trade-futures" target="_blank" rel="noreferrer noopener">How To Trade Futures</a>
Upcoming Economic Data
<ul>
<li>On Friday, the import price index data will be released at 8:30 a.m. ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) was 14.38% up in premarket after it saw a four-fold increase in AI connectivity revenue driven by Tomahawk and Jericho shipments. The management also highlighted a significant reduction in VMware spending in the fourth quarter.</li>
<li>RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) was up 17.23% after it raised revenue guidance across the board based on current trends.</li>
<li>Costco Wholesale Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) was up 0.3% in premarket after it reported its first-quarter revenue and earnings per share, which beat analyst estimates.</li>
<li>Inovio Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) was down 22.61% after it announced a proposed public offering.</li>
<li>Loop Industries Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOOP#NASDAQ">LOOP</a>) gained 51.22% as completed convertible preferred financing with Reed Societe Generale Group.</li>
<li>Repare Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>) tumbled 38.29% after it reported results of the Lunresertib and Camonsertib combination from MYTHIC Phase 1 gynecologic expansion clinical trial.</li>
<li>Candel Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAD#NASDAQ">CAD</a>) fell 31.12% after the company announced the pricing of its public offering.</li>
<li>Amentum Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMTM#NYSE">AMTM</a>) was up 0.6% ahead of its earnings which are slated to be released before the opening bell. Analysts expect the company to report quarterly earnings at 25 cents per share.</li>
<li>Investors are awaiting earnings results from 51Talk Online Education Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COE#NYSE">COE</a>) today.</li>
</ul>
Commodities, Bonds And Global Equity Markets:
Crude oil futures rose in the early New York session by 1.19% to hover around $70.86 per barrel.
The gold spot index fell by 0.88% to $2,685.59 per ounce. The Dollar Index was up 0.01% to 106.964 level.
Most Asian markets declined on Friday including Australia&#8217;s ASX 200, Hong Kong&#8217;s Hang Seng, China&#8217;s CSI 300, and Japan&#8217;s Nikkei 225. India&#8217;s S&amp;P BSE Sensex and South Korea&#8217;s Kospi Index, bucked the trend as they advanced. Most European markets advanced.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42460199/jpmorgan-reiterates-underweight-rating-on-supermicro-maintains-the-lowest-target-price-among-the-17-tracked-analysts">SMCI Stock Receives Harshest Price Target Among 17 Tracked Analysts As JPMorgan Maintains Underweight Rating On Super Micro</a></li>
</ul>
Photo courtesy: Wikimedia

Market Summary

Futures

Economics

Federal Reserve

ADBE

AMTM

NVDA

US Stocks Likely To Open Higher, Investors Eye Fed Policy Meet Next Week: Broadcom, RH, Costco In Focus

Shares of RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) rose sharply in the pre-market trading after the company <a href="https://www.benzinga.com/quote/RH/earnings">released quarterly results</a>.
RH posted downbeat earnings and sales results for its third quarter. However, the company raised revenue guidance across the board based on current trends. The company expects fourth-quarter demand growth of 20% to 22%, and fourth-quarter revenue growth of 18% to 20%, according to data from Benzinga Pro.
RH shares jumped 17.1% to $446.44 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Pearl Holdings Acquisition Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRLH#NASDAQ">PRLH</a>) gained 44.1% to $17.50 in pre-market trading after adding 4% on Thursday.</li>
<li>Loop Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOOP#NASDAQ">LOOP</a>) gained 41.3% to $1.74 in pre-market trading. Loop Industries completed convertible preferred financing with Reed Societe Generale Group.</li>
<li>SPI Energy Co., Ltd.. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPI#NASDAQ">SPI</a>) gained 39.5% to $0.4884 in pre-market trading after climbing around 14% on Thursday.</li>
<li>TruGolf Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUG#NASDAQ">TRUG</a>) gained 30.5% to $0.6785 in pre-market trading after jumping around 18% on Thursday.</li>
<li>Gaxos.ai Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GXAI#NASDAQ">GXAI</a>) rose 18.6% to $4.39 in pre-market trading after falling 27% on Thursday.</li>
<li>Lichen China Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LICN#NASDAQ">LICN</a>) gained 16% to $0.2272 in pre-market trading after dipping more than 25% on Thursday. Lichen China announced a $2.70 million registered direct offering.</li>
<li>Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) gained 14.8% to $207.50 in pre-market trading as the company posted better-than-expected earnings for its fourth quarter. The company said it sees first-quarter revenue of approximately $14.6 billion, versus the $14.612 billion estimate. The company also issued adjusted EBITDA guidance of approximately 66 percent of projected revenue for the first quarter.</li>
<li>EVgo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGO#NASDAQ">EVGO</a>) climbed 13.2% to $7.04 in pre-market trading. EVgo closed its $1.25 billion guaranteed loan facility from U.S. Department of Energy.</li>
<li>Lytus Technologies Holdings PTV. Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYT#NASDAQ">LYT</a>) gained 12.4% to $1.27 in pre-market trading after falling around 10% on Thursday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Repare Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>) shares tumbled 35.8% to $2.55 in pre-market trading after the company reported results of Lunresertib and Camonsertib combination from MYTHIC Phase 1 gynecologic expansion clinical trial.</li>
<li>Nuburu, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURU#NYSE">BURU</a>) declined 32.1% to $0.34 in pre-market trading after jumping 102% on Thursday.</li>
<li>Candel Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) shares fell 30.9% to $6.77 in pre-market trading after the company announced the pricing of public offering.</li>
<li>Inovio Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) fell 22.8% to $2.90 in pre-market trading after the company announced a proposed public offering.</li>
<li>Comstock Holding Companies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHCI#NASDAQ">CHCI</a>) dipped 17.8% to $7.00 in pre-market trading after declining 4% on Thursday.</li>
<li>Actuate Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACTU#NASDAQ">ACTU</a>) shares fell 15.5% to $7.00 in pre-market trading.</li>
<li>Northfield Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFBK#NASDAQ">NFBK</a>) fell 14.8% to $11.00 in pre-market trading.</li>
<li>SEALSQ Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NASDAQ">LAES</a>) shares dipped 13% to $1.61 in pre-market trading. SEALSQ announced the pricing of $10 million registered direct offering.</li>
<li>Pliant Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) fell 9.8% to $12.50 in today's pre-market trading.</li>
<li>Kimball Electronics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KE#NASDAQ">KE</a>) fell 4.5% to $18.32 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42460676/jim-cramer-amd-ceo-lisa-su-built-an-amazing-company">Jim Cramer Says This CEO &#8216;Built An Amazing Company,&#8217; Recommends Buying Netflix</a></li>
</ul>

ACTU

BURU

CHCI

EVGO

GXAI

LAES

LICN

NFBK

PLRX

PRLH

Why RH Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket

With U.S. stock futures trading mixed this morning on Friday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) posted downbeat earnings and sales results for its third quarter. However, the company raised revenue guidance across the board based on current trends. The company expects fourth-quarter demand growth of 20% to 22%, and fourth-quarter revenue growth of 18% to 20%, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. RH shares jumped 17.7% to $448.70 in the after-hours trading session.</li>
<li>Wall Street expects 51Talk Online Education Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COE#NYSE">COE</a>) to report its unaudited financial results for the third quarter ended Sept. 30, before the opening bell. 51Talk Online Education shares fell 2.9% to $17.00 in after-hours trading.</li>
<li>Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) posted better-than-expected earnings for its fourth quarter. The company said it sees first-quarter revenue of approximately $14.6 billion, versus the $14.612 billion estimate. The company also issued adjusted EBITDA guidance of approximately 66 percent of projected revenue for the first quarter. Broadcom shares jumped 14.1% to $206.10 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Inovio Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) announced a proposed public offering. Inovio Pharmaceuticals shares dipped 21% to $2.9696 in the after-hours trading session.</li>
<li>Costco Wholesale Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) reported upbeat results for its first quarter on Thursday. The company reported first-quarter revenue of $62.15 billion, beating the consensus estimate of $62.08 billion. Costco shares fell 0.6% to close at $988.39 on Thursday.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42460676/jim-cramer-amd-ceo-lisa-su-built-an-amazing-company">Jim Cramer Says This CEO &#8216;Built An Amazing Company,&#8217; Recommends Buying Netflix</a></li>
</ul>
Photo courtesy: Shutterstock

RH, Broadcom And 3 Stocks To Watch Heading Into Friday

Inovio Pharmaceuticals shares are trading lower after the company announced a proposed public offering with terms or size not yet disclosed.

Press Releases

Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients Observed in Phase 1/2 Trial

INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights

INOVIO Reports Inducement Grant Under Inducement Plan

New Retrospective Data Shows Half of RRP Patients Treated with INO-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 Trial

INOVIO Announces Proposed Public Offering

INOVIO Announces Pricing of $30 Million Public Offering

INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments

INOVIO to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Immune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference

Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications

Comments

Inovio Pharmaceuticals

Inovio Pharmaceuticals (INO) 옵션

Inovio Pharmaceuticals (NASDAQ:INO) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌